View Older Stories
-
Bristol Myers Squibb Prices €5 Billion of Senior Unsecured Notes
-
Bristol Myers Squibb Announces Cash Tender Offers to Purchase Certain Notes
-
Citi on Bristol-Myers Squibb Co. (BMY): 'ASCO 2025: Early stage ADCs support breadth of oncology portfolio'
-
Bristol Myers Squibb to Participate in Citi’s 2024 Global Healthcare Conference
-
Bristol-Myers Squibb-backed Zenas BioPharma files for US IPO
-
Citi Reiterates Buy Rating on Bristol-Myers Squibb Co. (BMY)
-
Bristol Myers Squibb Completes Acquisition of PureTech's Founded Entity Karuna Therapeutics for $14 Billion
-
Bristol-Myers Squibb (BMY) Completes Acquisition of Karuna Therapeutics (KRTX)
-
Bristol Myers Squibb Completes Acquisition of Karuna Therapeutics, Strengthening Neuroscience Portfolio
-
Bristol-Myers Squibb (BMY) Issues $13B of Notes to Fund Acquisitions
-
Bristol Myers Squibb Prices $13 Billion of Senior Unsecured Notes
-
PureTech Founded Entity Karuna Therapeutics to be Acquired by Bristol Myers Squibb for $14 Billion
-
Bristol-Myers Squibb (BMY) to Acquire Karuna Therapeutics (KRTX) for $330/sh or $14B
-
Bristol Myers Squibb Strengthens Neuroscience Portfolio with Acquisition of Karuna Therapeutics
-
Midday movers: Microsoft, Boeing, Bristol-Myers Squibb, and more
-
Citi on Bristol-Myers Squibb Co. (BMY): 'Major Opportunity in AF Remains but BMY Likely Needs to Pivot'
-
Bristol-Myers Squibb (BMY) Prices $4.5B Senior Unsecured Notes Offering
-
Bristol Myers Squibb Prices $4.5 Billion of Senior Unsecured Notes
-
Pre-Open Stock Movers: Bristol-Myers Jumps on FDA Approval, Carvana Gains on Upgrade
-
Bristol Myers Squibb to Participate in Citi’s 17th Annual BioPharma Conference
-
Citi Reiterates $90 PT on Bristol-Myers Squibb Co. (BMY), 'We expect some FTC scrutiny...but given the Pfizer/ Arena outcome, we remain hopeful'
-
Buffett's Berkshire Hathaway Enters 8 New Stocks, Including Citi and Paramount Global; Adds to Apple and Chevron
-
2 Reasons Why Citi Downgraded Merck (MRK) to Neutral Today, Opened a Negative Catalyst Watch
-
Bristol Myers Squibb Prices $7 Billion of Senior Unsecured Notes
-
Pre-Open Stock Movers 10/05: (MYOK) (KOS) (EIDX) Higher; (BBIO) (AMC) (DKNG) Lower (more...)
-
Bristol Myers Squibb to Participate in Citi’s 15th Annual BioPharma Virtual Conference
-
S&P 500 Buybacks Up 3.2% in Q4, Grim Outlook for 2020
-
S&P 500 buybacks up 3.2% in Q4 2019; Full Year 2019 down 9.6% from record 2018, as companies brace for a more volatile 2020
-
Citi Resumes Bristol-Myers Squibb Co. (BMY) at Buy
-
Dealmakers eye cross-border M&A recovery as mega mergers roll on
-
Choppy markets leave U.S. bank bonus decisions in limbo
-
Bristol-Myers Squibb (BMY) Completes Acquisition of Celgene (CELG)
-
Bristol-Myers Squibb Completes Acquisition of Celgene, Creating a Leading Biopharma Company
-
Bristol-Myers to buy Celgene for $74 billion in largest biopharma deal
-
Bristol-Myers Squibb (BMY) to Acquire Celgene Corp. (CELG) for Approx. $74B
-
Bristol-Myers Squibb to Acquire Celgene to Create a Premier Innovative Biopharma Company
-
Bristol-Myers Squibb to Take Part in Citi 2018 Global Healthcare Conference
-
Merck (MRK) Added to Citi Recommended List, Bristol-Myers Squibb (BMY) Removed
-
Pre-Open Movers 10/22: (ARII) (DVAX) (PETS) Higher; (MRTX) (HAS) (BMY) Lower (more...)
-
Citi Downgrades Bristol-Myers Squibb Co. (BMY) to Neutral
-
Omega's 13F Shows Increase in Ocwen (OCN), Synchrony (SYF), United (UAL), Exits Zynga (ZNGA) (More...)
-
Bristol-Myers Squibb Co. (BMY) PT Lowered to $62 at Citi
-
Pfizer (PFE) Made It Clear It Has No Interest in Bristol-Myers Squibb (BMY) - Citi
-
Bristol-Myers Squibb (BMY): Cutting PT As PFE Backs Away - Citi
-
Bristol-Myers Squibb to Take Part at the Citi 2017 Global Healthcare Conference
-
Pre-Open Movers 10/30: (CAA) (ADMS) (DYN) Higher; (PSTI) (CTB) (CENX) Lower (more...)
-
Bristol-Myers Squibb (BMY): Raising PT To $72 - Citi
-
Pre-Open Movers 08/16: (URBN) (TGT) (A) (PSTI) (MYL (BMY)
-
S&P 500 Buybacks Fall 17.5% Year-over-Year to $133.1 Billion for Q1 2017
-
Citi Downgrades Pfizer (PFE) to Sell; Risk to EPS Consensus, Needs Major Deal to Hit Numbers

